Giuseppe Saglio, MD, University of Turin, Turin, Italy, shares some insights into the current standard of care in chronic myeloid leukemia (CML), highlighting the costs and applications of currently available tyrosine kinase inhibitors (TKIs). Dr Saglio explains that first-generation TKIs such as imatinib are largely affordable, although this may differ between countries due to political and economical reasons. By comparison, second-generation TKIs such as nilotinib, dasatinib, and bosutinib are typically more expensive but also more likely to benefit subgroups of patients that require rapid, deep molecular responses. Following this, Dr Saglio acknowledges that a percentage of relapsed/refractory (R/R) patients may require third-line TKI therapy or stem cell transplantation. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
